Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a report released on Tuesday.

The analysts wrote, “We recently hosted a series of mtgs w/ investors and Theravance mgmt. TD-1473 JAK inhibitor and GSK respiratory programs were typical starting points for discussion. Mgmt plans to initiate TD-1473 Phase 2b induction/ maintenance trial in Ulcerative Colitis in mid-2018. Initial data from TD-1473 Phase 1b trial in this indication are consistent w/activity in our opinion. Number of doses and patients in Phase 2b trial will depend on data from additional Phase 1b cohorts, which mgmt has not yet seen. GSK launched Trelegy for COPD last month (5.5-8.5% royalty to Theravance). Significant time also spent on TD-9855 and velusetrag, both of which appear on path for Phase 3 initiation in 2018. Reiterate BUY. We believe stock is undervalued ($1.3B EV), given continued maturation of diversified pipeline.””

A number of other brokerages have also recently weighed in on TBPH. Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Evercore ISI started coverage on shares of Theravance Biopharma in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $45.00 price objective for the company. Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. ValuEngine upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday, September 13th. Finally, Robert W. Baird restated a “sell” rating and issued a $22.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $41.86.

Theravance Biopharma (NASDAQ TBPH) traded down $0.05 during midday trading on Tuesday, reaching $26.80. 179,771 shares of the company’s stock were exchanged, compared to its average volume of 236,120. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21. Theravance Biopharma has a 1 year low of $23.15 and a 1 year high of $43.44.

In other news, EVP Bradford J. Shafer sold 14,670 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $30.77, for a total value of $451,395.90. Following the completion of the sale, the executive vice president now directly owns 134,327 shares in the company, valued at $4,133,241.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.10% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC increased its position in Theravance Biopharma by 1.5% during the second quarter. Parametric Portfolio Associates LLC now owns 14,307 shares of the biopharmaceutical company’s stock worth $570,000 after acquiring an additional 217 shares during the period. Ameritas Investment Partners Inc. increased its position in Theravance Biopharma by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 230 shares during the period. SG Americas Securities LLC increased its position in Theravance Biopharma by 8.1% during the second quarter. SG Americas Securities LLC now owns 5,931 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 443 shares during the period. Legal & General Group Plc increased its position in Theravance Biopharma by 3.7% during the second quarter. Legal & General Group Plc now owns 16,289 shares of the biopharmaceutical company’s stock worth $649,000 after acquiring an additional 576 shares during the period. Finally, Zacks Investment Management increased its position in Theravance Biopharma by 4.6% during the second quarter. Zacks Investment Management now owns 21,603 shares of the biopharmaceutical company’s stock worth $861,000 after acquiring an additional 959 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Needham & Company LLC Reaffirms Buy Rating for Theravance Biopharma (TBPH)” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/05/needham-company-llc-reaffirms-buy-rating-for-theravance-biopharma-tbph.html.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.